Real-World Analysis of the Efficacy of Bimatoprost Sustained-Release Glaucoma Implant Where American Indians Comprise the Largest Minority Population
Steven R Sarkisian Jr,1 Evann C Mitchell2 1Research & Clinical Trials, Oklahoma Eye Surgeons, Oklahoma City, OK, USA; 2College of Medicine, University of Oklahoma, Oklahoma City, OK, USACorrespondence: Steven R Sarkisian Jr, Research & Clinical Trials, Oklahoma Eye Surgeons, 5600 N Portland...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2024-03-01
|
| Series: | Clinical Ophthalmology |
| Subjects: | |
| Online Access: | https://www.dovepress.com/real-world-analysis-of-the-efficacy-of-bimatoprost-sustained-release-g-peer-reviewed-fulltext-article-OPTH |
| _version_ | 1797246922079076352 |
|---|---|
| author | Sarkisian Jr SR Mitchell EC |
| author_facet | Sarkisian Jr SR Mitchell EC |
| author_sort | Sarkisian Jr SR |
| collection | DOAJ |
| description | Steven R Sarkisian Jr,1 Evann C Mitchell2 1Research & Clinical Trials, Oklahoma Eye Surgeons, Oklahoma City, OK, USA; 2College of Medicine, University of Oklahoma, Oklahoma City, OK, USACorrespondence: Steven R Sarkisian Jr, Research & Clinical Trials, Oklahoma Eye Surgeons, 5600 N Portland Ave, Oklahoma City, OK, 73112, USA, Tel +1405 943-4413, Fax +1405 942-0115, Email research@okeyesurgeons.comPurpose: To assess the effectiveness and safety of bimatoprost sustained release (SR) glaucoma implant as a treatment for open-angle glaucoma and ocular hypertension in a real-world private practice setting with a significant American Indian population.Methods: This retrospective study included 156 eyes from adult patients who received a single injection of bimatoprost implant between June 2020 and May 2022 at the Oklahoma Eye Surgeons. Patients were stratified by baseline intraocular pressure (IOP) (≥ 21 mmHg versus IOP< 21 mmHg). The co-primary endpoints were changes in the mean IOP and the number of topical IOP-lowering medications from baseline to Month 6.Results: At 6 months, eyes with baseline IOP≥ 21 mmHg had a significantly lower mean IOP (19.85± 8.01 versus 26.25± 4.84 mmHg; p< 0.0001) and the mean number of IOP-lowering medications (1.04± 1.44 versus 1.38± 1.50; p=0.048) compared with baseline. One year after implantation, 73.58% of eyes had a ≥ 20% reduction in IOP, 41.51% were medication-free and 30.19% were receiving at least one fewer medication. Among eyes with baseline IOP< 21 mmHg, there was a significant reduction in the mean number of IOP-lowering medicines by Month 6 (0.61± 1.03 versus 1.93± 1.21 at baseline; p< 0.0001), with no change in IOP. At 12 months, 24.27% of eyes had a ≥ 20% decrease in IOP, 43.69% of eyes did not require any medications and 63.11% had at least one fewer medication compared with baseline. An analysis using Welch’s two-sample t–test showed no significant differences in the outcomes between the overall population and the American Indian population (number of eyes, 23).Conclusion: Bimatoprost SR glaucoma implant lowered IOP in eyes with high, uncontrolled baseline IOP, while it reduced the number of medications in eyes with a controlled baseline IOP. No clinically meaningful and statistically significant differences in the efficacy of bimatoprost were observed in patients of American Indian descent.Keywords: intraocular pressure, open-angle glaucoma, ocular hypertension, prostaglandin analog, intracameral implant, ethnicity/race |
| first_indexed | 2024-04-24T19:50:29Z |
| format | Article |
| id | doaj.art-47a5516bd9f747b19a0d1a9a29b151ad |
| institution | Directory Open Access Journal |
| issn | 1177-5483 |
| language | English |
| last_indexed | 2024-04-24T19:50:29Z |
| publishDate | 2024-03-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Clinical Ophthalmology |
| spelling | doaj.art-47a5516bd9f747b19a0d1a9a29b151ad2024-03-24T16:49:44ZengDove Medical PressClinical Ophthalmology1177-54832024-03-01Volume 1891792791501Real-World Analysis of the Efficacy of Bimatoprost Sustained-Release Glaucoma Implant Where American Indians Comprise the Largest Minority PopulationSarkisian Jr SRMitchell ECSteven R Sarkisian Jr,1 Evann C Mitchell2 1Research & Clinical Trials, Oklahoma Eye Surgeons, Oklahoma City, OK, USA; 2College of Medicine, University of Oklahoma, Oklahoma City, OK, USACorrespondence: Steven R Sarkisian Jr, Research & Clinical Trials, Oklahoma Eye Surgeons, 5600 N Portland Ave, Oklahoma City, OK, 73112, USA, Tel +1405 943-4413, Fax +1405 942-0115, Email research@okeyesurgeons.comPurpose: To assess the effectiveness and safety of bimatoprost sustained release (SR) glaucoma implant as a treatment for open-angle glaucoma and ocular hypertension in a real-world private practice setting with a significant American Indian population.Methods: This retrospective study included 156 eyes from adult patients who received a single injection of bimatoprost implant between June 2020 and May 2022 at the Oklahoma Eye Surgeons. Patients were stratified by baseline intraocular pressure (IOP) (≥ 21 mmHg versus IOP< 21 mmHg). The co-primary endpoints were changes in the mean IOP and the number of topical IOP-lowering medications from baseline to Month 6.Results: At 6 months, eyes with baseline IOP≥ 21 mmHg had a significantly lower mean IOP (19.85± 8.01 versus 26.25± 4.84 mmHg; p< 0.0001) and the mean number of IOP-lowering medications (1.04± 1.44 versus 1.38± 1.50; p=0.048) compared with baseline. One year after implantation, 73.58% of eyes had a ≥ 20% reduction in IOP, 41.51% were medication-free and 30.19% were receiving at least one fewer medication. Among eyes with baseline IOP< 21 mmHg, there was a significant reduction in the mean number of IOP-lowering medicines by Month 6 (0.61± 1.03 versus 1.93± 1.21 at baseline; p< 0.0001), with no change in IOP. At 12 months, 24.27% of eyes had a ≥ 20% decrease in IOP, 43.69% of eyes did not require any medications and 63.11% had at least one fewer medication compared with baseline. An analysis using Welch’s two-sample t–test showed no significant differences in the outcomes between the overall population and the American Indian population (number of eyes, 23).Conclusion: Bimatoprost SR glaucoma implant lowered IOP in eyes with high, uncontrolled baseline IOP, while it reduced the number of medications in eyes with a controlled baseline IOP. No clinically meaningful and statistically significant differences in the efficacy of bimatoprost were observed in patients of American Indian descent.Keywords: intraocular pressure, open-angle glaucoma, ocular hypertension, prostaglandin analog, intracameral implant, ethnicity/racehttps://www.dovepress.com/real-world-analysis-of-the-efficacy-of-bimatoprost-sustained-release-g-peer-reviewed-fulltext-article-OPTHintraocular pressureopen-angle glaucomaocular hypertensionprostaglandin analogintracameral implantethnicity/race |
| spellingShingle | Sarkisian Jr SR Mitchell EC Real-World Analysis of the Efficacy of Bimatoprost Sustained-Release Glaucoma Implant Where American Indians Comprise the Largest Minority Population Clinical Ophthalmology intraocular pressure open-angle glaucoma ocular hypertension prostaglandin analog intracameral implant ethnicity/race |
| title | Real-World Analysis of the Efficacy of Bimatoprost Sustained-Release Glaucoma Implant Where American Indians Comprise the Largest Minority Population |
| title_full | Real-World Analysis of the Efficacy of Bimatoprost Sustained-Release Glaucoma Implant Where American Indians Comprise the Largest Minority Population |
| title_fullStr | Real-World Analysis of the Efficacy of Bimatoprost Sustained-Release Glaucoma Implant Where American Indians Comprise the Largest Minority Population |
| title_full_unstemmed | Real-World Analysis of the Efficacy of Bimatoprost Sustained-Release Glaucoma Implant Where American Indians Comprise the Largest Minority Population |
| title_short | Real-World Analysis of the Efficacy of Bimatoprost Sustained-Release Glaucoma Implant Where American Indians Comprise the Largest Minority Population |
| title_sort | real world analysis of the efficacy of bimatoprost sustained release glaucoma implant where american indians comprise the largest minority population |
| topic | intraocular pressure open-angle glaucoma ocular hypertension prostaglandin analog intracameral implant ethnicity/race |
| url | https://www.dovepress.com/real-world-analysis-of-the-efficacy-of-bimatoprost-sustained-release-g-peer-reviewed-fulltext-article-OPTH |
| work_keys_str_mv | AT sarkisianjrsr realworldanalysisoftheefficacyofbimatoprostsustainedreleaseglaucomaimplantwhereamericanindianscomprisethelargestminoritypopulation AT mitchellec realworldanalysisoftheefficacyofbimatoprostsustainedreleaseglaucomaimplantwhereamericanindianscomprisethelargestminoritypopulation |